CO2021007077A2 - Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos - Google Patents
Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estosInfo
- Publication number
- CO2021007077A2 CO2021007077A2 CONC2021/0007077A CO2021007077A CO2021007077A2 CO 2021007077 A2 CO2021007077 A2 CO 2021007077A2 CO 2021007077 A CO2021007077 A CO 2021007077A CO 2021007077 A2 CO2021007077 A2 CO 2021007077A2
- Authority
- CO
- Colombia
- Prior art keywords
- antigen
- muc16
- bispecific
- binding molecules
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
RESUMEN La presente invención proporciona moléculas de fijación al antígeno biespecíficas que comprenden un primer dominio de fijación al antígeno que se fija específicamente a CD28 humana, y un segundo dominio de fijación al antígeno que se fija específicamente a MUC16 humana. En ciertas formas de realización, las moléculas de fijación al antígeno biespecíficas de la presente invención pueden inhibir el crecimiento de tumores que expresan MUC16, tales como tumores de ovario. Los anticuerpos y las moléculas de fijación al antígeno biespecíficas de la invención son útiles para el tratamiento de enfermedades y trastornos en los que una respuesta inmunitaria dirigida regulada de manera ascendente o inducida es conveniente y/o terapéuticamente beneficiosa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862782142P | 2018-12-19 | 2018-12-19 | |
US201962815861P | 2019-03-08 | 2019-03-08 | |
PCT/US2019/067109 WO2020132024A1 (en) | 2018-12-19 | 2019-12-18 | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021007077A2 true CO2021007077A2 (es) | 2021-06-10 |
Family
ID=69182675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0007077A CO2021007077A2 (es) | 2018-12-19 | 2021-05-28 | Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos |
Country Status (16)
Country | Link |
---|---|
US (2) | US11453721B2 (es) |
EP (1) | EP3898695A1 (es) |
JP (1) | JP2022515611A (es) |
KR (1) | KR20210104758A (es) |
CN (1) | CN113166268A (es) |
AU (1) | AU2019405736A1 (es) |
BR (1) | BR112021010457A2 (es) |
CA (1) | CA3123420A1 (es) |
CL (1) | CL2021001573A1 (es) |
CO (1) | CO2021007077A2 (es) |
IL (1) | IL283493A (es) |
MA (1) | MA54539A (es) |
MX (1) | MX2021006971A (es) |
PH (1) | PH12021551238A1 (es) |
SG (1) | SG11202105948TA (es) |
WO (1) | WO2020132024A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020013804A (es) * | 2018-06-21 | 2021-03-31 | Regeneron Pharma | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. |
WO2022040482A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
CN111925990B (zh) * | 2020-09-02 | 2022-08-26 | 北京立康生命科技有限公司 | 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法 |
KR20230070259A (ko) | 2020-09-18 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd38 및/또는 cd28에 결합하는 항원 결합 분자, 및 이의 용도 |
CA3204161A1 (en) | 2021-01-11 | 2022-07-14 | Jagesh Vijaykumar SHAH | Use of cd8-targeted viral vectors |
EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向cd4之病毒載體之用途 |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
US20240002544A1 (en) | 2022-03-07 | 2024-01-04 | Novimmune Sa | Cd28 bispecific antibodies for targeted t cell activation |
US20230287146A1 (en) | 2022-03-14 | 2023-09-14 | LamKap Bio gamma AG | BISPECIFIC GPC3xCD28 AND GPC3xCD3 ANTIBODIES AND THEIR COMBINATION FOR TARGETED KILLING OF GPC3 POSITIVE MALIGNANT CELLS |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023198042A1 (zh) * | 2022-04-11 | 2023-10-19 | 江苏恒瑞医药股份有限公司 | 特异性结合egfr和cd28的抗原结合分子及其医药用途 |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US20040116675A1 (en) | 2001-12-14 | 2004-06-17 | Tso J. Jun | Silenced anti-cd28 antibodies and use thereof |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
MY159787A (en) | 2006-06-02 | 2017-01-31 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
CN105636982B (zh) * | 2013-09-16 | 2020-06-23 | 健康与环境慕尼黑德国研究中心赫姆霍茨中心(有限责任公司) | 用于治疗hbv感染和相关病症的结合免疫效应细胞表面抗原和hbv抗原的双或多特异性多肽 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
CA2999385A1 (en) | 2015-09-23 | 2017-03-30 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
MD3515487T2 (ro) * | 2016-09-23 | 2023-11-30 | Regeneron Pharma | Anticorpi bispecifici anti-MUC16-CD3 și conjugate anticorp anti-MUC16-medicament |
CA3037732A1 (en) | 2016-09-23 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
-
2019
- 2019-12-18 JP JP2021535639A patent/JP2022515611A/ja active Pending
- 2019-12-18 BR BR112021010457-7A patent/BR112021010457A2/pt unknown
- 2019-12-18 CA CA3123420A patent/CA3123420A1/en active Pending
- 2019-12-18 AU AU2019405736A patent/AU2019405736A1/en active Pending
- 2019-12-18 CN CN201980080509.2A patent/CN113166268A/zh active Pending
- 2019-12-18 EP EP19839545.1A patent/EP3898695A1/en active Pending
- 2019-12-18 US US16/719,273 patent/US11453721B2/en active Active
- 2019-12-18 WO PCT/US2019/067109 patent/WO2020132024A1/en active Application Filing
- 2019-12-18 MX MX2021006971A patent/MX2021006971A/es unknown
- 2019-12-18 SG SG11202105948TA patent/SG11202105948TA/en unknown
- 2019-12-18 KR KR1020217021119A patent/KR20210104758A/ko unknown
- 2019-12-18 MA MA054539A patent/MA54539A/fr unknown
-
2021
- 2021-05-27 IL IL283493A patent/IL283493A/en unknown
- 2021-05-28 PH PH12021551238A patent/PH12021551238A1/en unknown
- 2021-05-28 CO CONC2021/0007077A patent/CO2021007077A2/es unknown
- 2021-06-15 CL CL2021001573A patent/CL2021001573A1/es unknown
-
2022
- 2022-08-17 US US17/890,078 patent/US20230279113A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210104758A (ko) | 2021-08-25 |
MA54539A (fr) | 2021-10-27 |
CA3123420A1 (en) | 2020-06-25 |
CL2021001573A1 (es) | 2021-11-26 |
MX2021006971A (es) | 2021-07-15 |
CN113166268A (zh) | 2021-07-23 |
US11453721B2 (en) | 2022-09-27 |
PH12021551238A1 (en) | 2021-12-13 |
JP2022515611A (ja) | 2022-02-21 |
EP3898695A1 (en) | 2021-10-27 |
US20200199233A1 (en) | 2020-06-25 |
WO2020132024A1 (en) | 2020-06-25 |
IL283493A (en) | 2021-07-29 |
AU2019405736A1 (en) | 2021-06-24 |
US20230279113A1 (en) | 2023-09-07 |
SG11202105948TA (en) | 2021-07-29 |
BR112021010457A2 (pt) | 2021-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021007077A2 (es) | Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos | |
CL2020003285A1 (es) | Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos. | |
CO2021009004A2 (es) | Anticuerpos biespecíficos anti-cd28 x anti-cd22 y usos de estos | |
CL2020003179A1 (es) | (divisional de solicitud 713-2015) anticuerpos anti-cd3, moleculas de union a antígeno biespecificas que se unen a cd3 y cd20; y usos de los mismos. | |
CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
CO2020014575A2 (es) | Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos | |
CO2019003923A2 (es) | Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos | |
CO2021016768A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
CL2021002645A1 (es) | Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos. (divisional de solicitud 201900726) | |
CO2021016765A2 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y métodos de uso de estos | |
AR106570A1 (es) | Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos | |
CL2021000142A1 (es) | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos. | |
ECSP19029758A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
CL2018002810A1 (es) | Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada. | |
ECSP22015044A (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
CO2021014768A2 (es) | Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares | |
CO2022003324A2 (es) | Anticuerpos anti-nrp1a y sus usos para tratar enfermedades oculares | |
DOP2019000082A (es) | Anticuerpos anti-il-33 y usos de los mismos | |
EA202191677A1 (ru) | Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения | |
CO2021003608A2 (es) | Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos | |
AR119536A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
AR118787A1 (es) | Moléculas de unión a pd-l1 y uso de las mismas para el tratamiento de enfermedades |